Related Content
- Communiqué: Evaluation of Bleeding Symptoms, Disorders, and Risks - Evaluation for von Willebrand Disease
- Communiqué: Warfarin: Genotyping and Improving Dosing
- Communiqué: How to Interpret and Pursue an Abnormal Prothrombin Time, Activated Partial Thromboplastin Time, and Bleeding Time in Adults
- Communiqué: A Practical Approach to Testing for Von Willebrand Disease
- Communiqué: How to Interpret and Pursue an Abnormal Complete Blood Cell Count in Adults
- Communiqué: Importance of Device Evaluation for Point-of-Care Prothrombin Time International Normalized Ratio Testing Programs
- Communiqué: Essential Thrombocythemia
- Communiqué: The Diagnosis and Treatment of Hypercoagulability States
- Hot Topic: Warfarin Sensitivity Genotyping
- Hot Topic: Middleware and the Clinical Hematology Laboratory
- Hot Topic: Preparation of Platelet Poor Plasma for Special Coagulation Testing
- Hot Topic: Preanalytic Variables in Special Coagulation Testing: Clinical Implications
- Hot Topic: Platelet Esoteric Testing - A Case Study
- Algorithm: Coagulation | Von Willebrand Disease Profile
- Hot Topic: Von Willebrand Disease (VWD) Part 1: NHLBI Diagnosis Guidelines
- Hot Topic: Von Willebrand Disease (VWD) Part 2: NHLBI Diagnosis Guidelines
- Hot Topic: Guidelines for Anticoagulation Therapy for Secondary Prevention After Deep Vein Thrombosis
- Hot Topic: Von Willebrand Disease (VWD) Part 3: VWF Activity Assay
- Hot Topic: Clopidogrel Platelet Function Tests
External
link
PDF
document
Excel
document
Word
document